Abbvie Inc.

Abbott Laboratories Corporation

Epimab Biotherapeutics, Inc.

Shanghai Epimab Biotherapeutics Co., Ltd.

Chengbin Wu

Tariq Ghayur

Dominic J Ambrosi

Chung-Ming Hsieh

Richard W Dixon

Carolyn A Cuff

Yan Chen

Shankar Kumar

Paul Robert Hinton

Maria A Argiriadi

Jonathan P Belk

Hua Ying

Terry L Melim

Jochen G Salfeld

Chung-ming Hsieh

Rajesh Vasant Kamath

Lisa Maria Olson

Hamish John Allen

Margaret Hugunin

Peter C Isakson

Renee Miller

Shiyong Gong

Xuan Wu

High-affinity antibodies recognizing Programmed Death Ligand-1 (PD-1) and Lymphocyte Activation Gene 3 protein (LAG-3) are disclosed. Binding sites from humanized anti-PD-1 and anti-LAG-3 antibodies are incorporated into a Fabs-in-Tandem Immunoglobulin format without significant loss of binding affinity, and the resultant bispecific, multivalent binding proteins are able to bind to both PD-1 and LAG-3 simultaneously. Such bispecific FIT-Ig binding proteins are useful for treatment of cancer.

High affinity antibodies to PD-1 and LAG-3 and bispecific binding proteins made therefrom

The present invention provides multivalent and multispecific binding proteins that are capable of binding two or more antigens, or two or more epitopes. The present invention also provides methods of making and using such multivalent and multispecific binding proteins, including methods of using such binding proteins for prevention or treatment of various diseases, or for detecting specific antigens in vitro or in vivo.

Fabs-in-tandem immunoglobulin and uses thereof

The present invention encompasses IL-13 binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-13 and neutralize hIL-13 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-13 and for inhibiting hIL-13 activity, e.g., in a human subject suffering from a disorder in which hIL-13 activity is detrimental.

Interleukin-13 binding proteins

Proteins that bind IL-1&#x3b1; and IL-1&#x3b2; are described along with their use in compositions and methods for treating, preventing, and diagnosing IL-1-related disorders and for detecting IL-1&#x3b1; and IL-1&#x3b2; in cells, tissues, samples, and compositions.

IL-1 binding proteins

The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Dual variable domain immunoglobulins and uses thereof

Dual variable domain immunnoglobulins and uses thereof

Growing community of inventors

Shanghai, China

Chengbin Wu